Straits Times Index
3,077.40 +0.24 (+0.01%) Nikkei
33,445.90 +670.08 (+2.04%) Hang Seng
16,449.86 +122.00 (+0.75%) FTSE 100
7,489.84 -23.12 (-0.31%) Bitcoin USD
43,706.18 +2,199.21 (+5.30%) CMC Crypto 200
893.23 +32.68 (+3.80%)
ABT Jun 2024 145.000 call
| Previous close | 0.0500 |
| Open | 0.0600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 145.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Insider Monkey12 Best Healthcare Dividend Stocks To Buy Now
In this article, we discuss 12 best healthcare dividend stocks to buy now. You can skip our detailed analysis of the healthcare sector and the past performance of dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks To Buy Now. Over the span of almost four years, the COVID-19 pandemic brought about […]
ZacksAbbott (ABT) Rises Higher Than Market: Key Facts
Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session.
Motley FoolAbbVie Should Consider a Dividend Cut -- Here's Why
Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of Dividend Kings. AbbVie's top-shelf performance has been due to two main factors. First up, the company successfully expanded Humira's label at a breakneck pace over this period, transforming it into the world's first pharma product to exceed $20 billion a year in sales.
